Serial 88956376
Dead / Abandoned — Abandoned — no statement of use filed (as of 04 Mar 2024)
What this means for you
This application is over — abandoned 04 Mar 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88956376
- Mark type
- Design / logo
- Filed
- 09 Jun 2020
- Published for opposition
- 08 Dec 2020
- Abandoned
- 04 Mar 2024
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
- Class 042 — Scientific and technological services: scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
- Class 044 — Medical, beauty and agricultural services: providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Owner
- CytoDyn Inc., Vancouver, WA, US
- CytoDyn Inc., Vancouver, WA, US
Prosecution history
- 04 Mar 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 04 Mar 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 11 Aug 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Aug 2023 — SOU EXTENSION 5 GRANTED
- 02 Aug 2023 — SOU EXTENSION 5 FILED
- 10 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 Aug 2023 — SOU TEAS EXTENSION RECEIVED
- 13 Jan 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jan 2023 — SOU EXTENSION 4 GRANTED
- 11 Jan 2023 — SOU EXTENSION 4 FILED
- 11 Jan 2023 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2022 — SOU EXTENSION 3 GRANTED
- 24 Jun 2022 — SOU EXTENSION 3 FILED
- 24 Jun 2022 — SOU TEAS EXTENSION RECEIVED